{"id":"W3130386910","doi":"10.1016/j.jcin.2020.11.046","title":"Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI","year":2021,"lang":"en","type":"review","venue":"JACC: Cardiovascular Interventions","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; National Human Genome Research Institute; Amarin Pharma; Abbott Vascular; GE Healthcare; St. Jude Medical; National Center for Advancing Translational Sciences; Johnson and Johnson; National Institutes of Health; Defence Science Institute; Duke Clinical Research Institute; Eisai; Janssen Scientific Affairs; British Heart Foundation; OrbusNeich; Siemens Medical Solutions USA; Medicines Company; Boston Scientific Corporation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Foundation for Cardiovascular Research; Bayer; Gilead Sciences; University of Florida; Medtronic; Abbott Laboratories; CSL Behring; Chiesi Farmaceutici; AstraZeneca; Bristol-Myers Squibb; Scott R. MacKenzie Foundation; Portola Pharmaceuticals; Boehringer Ingelheim; Amgen; Merck","keywords":"Ticagrelor; Conventional PCI; Medicine; Dual (grammatical number); Cardiology; Internal medicine; Percutaneous coronary intervention; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008524257,0.0008205148,0.003468079,0.001410389,0.0001750116,0.0009610539,0.0008820351,0.0009360856,0.005632783],"category_scores_gemma":[0.00166643,0.0002980832,0.001993092,0.001843059,0.0002065755,0.0006363468,0.0004451815,0.001491253,0.0006894778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004883563,"about_ca_system_score_gemma":0.0008362529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001360681,"about_ca_topic_score_gemma":0.003836636,"domain_scores_codex":[0.9996389,0.00009101024,0.00009348364,0.00005790306,0.0000835035,0.00003514005],"domain_scores_gemma":[0.9993487,0.0004193052,0.0001424937,0.0000103108,0.00005481349,0.00002441476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.002260755,0.000161246,0.0004149223,0.1550954,0.005524004,0.0001306616,0.00004233123,0.0002635013,0.001024135,0.0009924321,0.01946652,0.8146241],"study_design_scores_gemma":[0.008408191,0.004070325,0.01909169,0.2000197,0.08599581,0.002853608,0.0003062156,0.001058796,0.001663344,0.003983743,0.672385,0.0001635471],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002411857,0.9991709,0.00003429383,0.00007024308,0.0001108506,0.000007402859,0.00002097368,0.000002491146,0.0003416344],"genre_scores_gemma":[0.002315496,0.9969421,0.0001227332,0.0002090211,0.0001713822,0.0000135994,0.00005028231,0.000001342165,0.0001741145],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005632783,"threshold_uncertainty_score":0.01884353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1403258687003857,"score_gpt":0.3872493015605913,"score_spread":0.2469234328602056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}